Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (7157)	9/3/1998 3:58:00 PM
From: Edward Paule	Read Replies (2) \| Respond to of 17367

B'green, I agree with you. I speculated about the DSMB September meeting back in post #6398 on 6/1/98: Message 4670266 Basically, the original trial design had only two scheduled interim analysis looks by the DSMB. At the second review, the DSMB itself suggested that a third look occur in September. My speculation was that the DSMB knew the data was good, but refrained from stopping the trial because they only had 130 patients. They knew that if the data remained good that 200 patients (September) it would be statistically significant enough to stop the trial. They felt it would be unethical to allow the trial to run through December. IMO, Ed.